Human IGSF3 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF4788
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Mouse
Applications
Validated:
CyTOF-ready, Flow Cytometry, Western Blot
Cited:
Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Sheep IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human IGSF3
Gln20-Ala1125
Accession # AAI10652
Gln20-Ala1125
Accession # AAI10652
Specificity
Detects human IGSF3 in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Sheep
Isotype
IgG
Scientific Data Images for Human IGSF3 Antibody
Detection of IGSF3 in A549 Human Cell Line by Flow Cytometry.
A549 human lung carcinoma cell line was stained with Sheep Anti-Human IGSF3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4788, filled histogram) or control antibody (Catalog # 5-001-A, open histogram), followed by NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # NL010).
Detection of Human IGSF3 by Western Blot.
Western blot shows lysates of human lung tissue. PVDF membrane was probed with 1 µg/mL of Sheep Anti-Human IGSF3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4788) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for IGSF3 at approximately 200 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 1.Applications for Human IGSF3 Antibody
Application
Recommended Usage
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
Flow Cytometry
2.5 µg/106 cells
Sample: A549 human lung carcinoma cell line
Sample: A549 human lung carcinoma cell line
Western Blot
Human lung tissue under non-reducing conditions only
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IGSF3
IGSF3 (Immunoglobulin superfamily member 3; also EWI-3) is a 133 kDa (predicted) member of the EWI subfamily of the Ig-Superfamily of molecules. It is reported to be widely expressed, with concentration in placenta and lung. Human IGSF3 an 1194 amino acid (aa) type I transmembrane protein that contains a 19 aa signal sequence followed by an 1175 aa mature region (aa 20-1194) (SwissProt # O75054). The molecule's extracellular region is 1105 aa in length (aa 20-1124), and contains eight C2-type Ig-like domains (aa 22-1097). This region also possesses at least two utilized phosphorylation sites at Thr617and Ser625, plus an EWI motif in the second Ig-like domain. IGSF3 likely exists as a disulfide-linked homodimer. There are two potential isoform variants. One contains a 20 aa insertion after Pro406, while another shows the same insert coupled to a premature truncation after Pro833. GenBank Accession # AAI10652 is identical to the SwissProt sequence above save for a double Glu substitution for Asp1020 in the eighth Ig-like domain. Over aa 20‑1125, human IGSF3 shares 92% aa identity with mouse IGSF3.
Long Name
Immunoglobulin Superfamily, Member 3
Alternate Names
EWI-3, V8
Gene Symbol
IGSF3
UniProt
Additional IGSF3 Products
Product Documents for Human IGSF3 Antibody
Product Specific Notices for Human IGSF3 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...